BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study
Top Cited Papers
- 1 February 2002
- journal article
- Published by Elsevier in The Lancet
- Vol. 359 (9305), 487-491
- https://doi.org/10.1016/s0140-6736(02)07679-1
Abstract
No abstract availableKeywords
Funding Information
- Bundesministerium für Bildung und Forschung (01-GS-0105, 01-GS-0155)
This publication has 13 references indexed in Scilit:
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid LeukemiaNew England Journal of Medicine, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplificationBlood, 2000
- The Biology of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene ProductsScience, 1990
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990